Enregistré dans:
Détails bibliographiques
Auteurs principaux: Christina Sharkey, Xingbo Long, Ra'ad Al‐Faouri, Douglas Strand, Aria F Olumi, Zongwei Wang
Format: Artículo Open Access
Publié: Wiley 2024
Sujets:
Accès en ligne:https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.6283
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
_version_ 1867020860041199616
author Christina Sharkey
Xingbo Long
Ra'ad Al‐Faouri
Douglas Strand
Aria F Olumi
Zongwei Wang
author_facet Christina Sharkey
Xingbo Long
Ra'ad Al‐Faouri
Douglas Strand
Aria F Olumi
Zongwei Wang
Christina Sharkey
Xingbo Long
Ra'ad Al‐Faouri
Douglas Strand
Aria F Olumi
Zongwei Wang
collection Wiley Open Access
contents Enhanced prostatic Esr1+ luminal epithelial cells in the absence of SRD5A2 Christina Sharkey Xingbo Long Ra'ad Al‐Faouri Douglas Strand Aria F Olumi Zongwei Wang The Journal of Pathology AbstractSteroid 5α reductase 2 (SRD5A2) converts testosterone to dihydrotestosterone and is crucial for prostatic development. 5α reductase inhibitors (5ARI) reduce prostate size in benign prostate hyperplasia (BPH) and ameliorate lower urinary tract symptoms secondary to BPH. However, the mechanisms of 5ARI functioning are still not fully understood. Here, we used a Srd5a2−/− mouse model and employed single‐cell RNA sequencing to explore the impact of SRD5A2 absence on prostate cellular heterogeneity. Significant alterations in luminal epithelial cell (LE) populations were observed, alongside an increased proportion and proliferative phenotype of estrogen receptor 1 (ESR1)+ LE2 cells, following an SRD5A2‐independent ESR1 differentiation trajectory. LE2 cells exhibited enhanced estrogen response gene signatures, suggesting an alternative pathway for prostate growth when SRD5A2 is absent. Human prostate biopsy analysis revealed an inverse correlation between the expressions of SRD5A2 and LE2 markers (ESR1/PKCα), and an inverse correlation between SRD5A2 and the clinical efficiency of 5ARI. These findings provide insights into 5ARI resistance mechanisms and potential alternative therapies for BPH‐related lower urinary tract symptoms. © 2024 The Pathological Society of Great Britain and Ireland. 10.1002/path.6283 http://onlinelibrary.wiley.com/termsAndConditions#vor
doi_str_mv 10.1002/path.6283
format Artículo Open Access
id wiley_oa_10_1002_path_6283
institution Wiley Open Access
license_str_mv http://onlinelibrary.wiley.com/termsAndConditions#vor
publishDate 2024
publisher Wiley
record_format wiley_oa
spellingShingle Enhanced prostatic Esr1+ luminal epithelial cells in the absence of SRD5A2
Christina Sharkey
Xingbo Long
Ra'ad Al‐Faouri
Douglas Strand
Aria F Olumi
Zongwei Wang
The Journal of Pathology
Enhanced prostatic Esr1+ luminal epithelial cells in the absence of SRD5A2 Christina Sharkey Xingbo Long Ra'ad Al‐Faouri Douglas Strand Aria F Olumi Zongwei Wang The Journal of Pathology AbstractSteroid 5α reductase 2 (SRD5A2) converts testosterone to dihydrotestosterone and is crucial for prostatic development. 5α reductase inhibitors (5ARI) reduce prostate size in benign prostate hyperplasia (BPH) and ameliorate lower urinary tract symptoms secondary to BPH. However, the mechanisms of 5ARI functioning are still not fully understood. Here, we used a Srd5a2−/− mouse model and employed single‐cell RNA sequencing to explore the impact of SRD5A2 absence on prostate cellular heterogeneity. Significant alterations in luminal epithelial cell (LE) populations were observed, alongside an increased proportion and proliferative phenotype of estrogen receptor 1 (ESR1)+ LE2 cells, following an SRD5A2‐independent ESR1 differentiation trajectory. LE2 cells exhibited enhanced estrogen response gene signatures, suggesting an alternative pathway for prostate growth when SRD5A2 is absent. Human prostate biopsy analysis revealed an inverse correlation between the expressions of SRD5A2 and LE2 markers (ESR1/PKCα), and an inverse correlation between SRD5A2 and the clinical efficiency of 5ARI. These findings provide insights into 5ARI resistance mechanisms and potential alternative therapies for BPH‐related lower urinary tract symptoms. © 2024 The Pathological Society of Great Britain and Ireland. 10.1002/path.6283 http://onlinelibrary.wiley.com/termsAndConditions#vor
title Enhanced prostatic Esr1+ luminal epithelial cells in the absence of SRD5A2
topic The Journal of Pathology
url https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.6283